Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Prevention |
RCV000249538 | SCV000305738 | benign | not specified | criteria provided, single submitter | clinical testing | ||
Athena Diagnostics Inc | RCV000992580 | SCV001144981 | benign | not provided | 2019-05-10 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001001963 | SCV001159763 | benign | Polycystic kidney disease, adult type | 2018-10-01 | criteria provided, single submitter | clinical testing | |
Gene |
RCV000992580 | SCV001864146 | benign | not provided | 2021-05-11 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 22383692) |
Department of Pathology and Laboratory Medicine, |
RCV001292180 | SCV001480829 | benign | Polycystic kidney disease | no assertion criteria provided | clinical testing | The PKD1 p.Ala1421= variant was identified in 3 of 550 proband chromosomes (frequency: 0.005) from individuals or families with ADPKD (Rossetti 2002, Rossetti 2012). The variant was also identified in dbSNP (ID: rs149938033) as “With Benign allele”, Clinvitae (classification benign), ClinVar (classification benign by Prevention Genetics), ADPKD Mutation Database (classification likely neutral), the 1000 Genomes Project in 16 of 5000 chromosomes (frequency: 0.003), HAPMAP-AFR in 16 of 1322 chromosomes (frequency: 0.01), NHLBI GO Exome Sequencing Project in 4 of 8592 European American American alleles (frequency: 0.0005) and in 52 of 4394 African American alleles (frequency: 0.01), and in the Exome Aggregation Consortium database (August 8, 2016) in 141 (2 homozygous) of 118562 chromosomes (frequency: 0.001), increasing the likelihood this could be a low frequency benign variant. In addition we cannot be certain that data from control databases is specific to PKD1 and not from one of the six PKD1 pseudogenes. The variant was not identified in GeneInsight COGR, MutDB, PKD1-LOVD, and PKD1-LOVD 3.0. The c.4263C>T variant is not expected to have clinical significance because it does not result in a change of amino acid and is not located in a known consensus splice site, occurring outside of the splicing consensus sequence. In addition one of five in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) predicting a greater than 10% difference in splicing; this is not very predictive of pathogenicity. The variant was identified with a co-occurring pathogenic PKD2 variant (c.709+1G>A, r.spl?), increasing the likelihood that the c.4263C>T variant does not have clinical significance. In summary, based on the above information, this variant meets our laboratory criteria to be classified as benign. |